Section 1: Compound Overview (Research Context Only)
CJC-1295 with DAC (Drug Affinity Complex) represents a structurally modified analogue of growth hormone-releasing hormone (GHRH) that incorporates a reactive maleimidopropionic acid (MPA) group at a defined position within its peptide sequence. This addition is not incidental. It was engineered specifically to enable spontaneous, covalent conjugation to endogenous serum albumin following systemic administration, a pharmacokinetic strategy that fundamentally distinguishes this compound from unmodified GHRH analogues or the DAC-free version of CJC-1295. The consequence of this conjugation is a dramatic extension of plasma half-life, from approximately 30 minutes in the unbound form to an estimated 6-8 days for the albumin-conjugated species, as characterized in preclinical rodent and primate pharmacokinetic studies.
Understanding the mechanistic basis for this half-life extension requires examining both the chemistry of the MPA-maleimide reactive group and the structural biology of serum albumin, particularly the reactivity of its free cysteine residue at position 34 (Cys34). CJC-1295 with DAC is studied strictly under research use only (RUO) conditions. The pharmacokinetic parameters described in this article are derived from preclinical data and are not applicable to clinical populations without formal investigational validation.
Section 2: Current Research Landscape
Serum albumin is the most abundant plasma protein in mammalian systems, with a circulating half-life of approximately 19-21 days in humans and analogous values in rodent and non-human primate models. This longevity results from neonatal Fc receptor (FcRn)-mediated recycling, which prevents lysosomal degradation and returns albumin to circulation after endosomal uptake. Albumin is also the primary carrier protein for a diverse array of endogenous ligands including fatty acids, bilirubin, hormones, and exogenous drugs. Its size, approximately 67 kDa, places it well above the renal filtration threshold, further protecting it from urinary clearance. When a peptide is covalently attached to albumin, it inherits these protective characteristics.
The specific site of covalent attachment exploited by the DAC technology is Cys34, the only free cysteine residue in human serum albumin. Cys34 carries a free thiol group (-SH) that is partially reduced under physiological conditions, meaning a proportion of circulating albumin molecules present a nucleophilic thiol available for reaction. In plasma, this residue is not buried within the protein core but occupies a partially solvent-exposed position within domain I, making it kinetically accessible to electrophilic reagents introduced systemically. The MPA group on CJC-1295 with DAC acts as precisely this kind of electrophilic trap, reacting selectively with the Cys34 thiol to form a stable thioether bond under physiological pH and temperature conditions.
Section 3: Systems Context
Maleimide-Thiol Chemistry and Thioether Bond Formation
The maleimidopropionic acid group attached to CJC-1295 participates in a Michael addition reaction with the sulfhydryl group of Cys34 on albumin. In this reaction, the sulfur atom of the thiol acts as a nucleophile, attacking the electrophilic carbon of the maleimide double bond. The initial product of this reaction is a thiosuccinimide adduct. Under physiological pH conditions, this thiosuccinimide ring can subsequently undergo hydrolysis to produce an open-chain thioether, a species that is chemically more stable and significantly more resistant to retro-Michael elimination than the closed-ring succinimide form. This hydrolysis step, which is pH-dependent and occurs spontaneously in plasma at physiological pH, converts the initially formed adduct into the kinetically stable thioether conjugate that defines the long-acting pharmacokinetic behavior of CJC-1295 with DAC.
Selectivity for Cys34 Over Other Plasma Thiols
Plasma contains multiple thiol-bearing species beyond albumin Cys34, including glutathione, cysteine, homocysteine, and thiol groups on other plasma proteins. The selectivity of the MPA-maleimide group for Cys34 over these competing nucleophiles is not absolute but is favored by several factors. Albumin is present at roughly 35-50 mg/mL in plasma, making it by far the most concentrated macromolecular thiol source. Low-molecular-weight thiols such as free cysteine are present at comparatively low concentrations and, critically, any conjugate formed with small molecules would not confer the same half-life extension because these small conjugates remain susceptible to renal filtration and metabolic clearance. The partial oxidation state of Cys34, where a fraction of albumin circulates with a free thiol while another fraction carries a mixed disulfide, introduces some variability in the fraction of circulating albumin available for conjugation at any given time, a consideration relevant to interpreting pharmacokinetic variability across individual subjects and species in preclinical studies.
Pharmacokinetic Parameters of the Conjugated Species
Preclinical characterization of CJC-1295 with DAC in rat and non-human primate models has established the pharmacokinetic profile of the albumin-conjugated species with reasonable consistency. Following subcutaneous administration, the compound undergoes gradual absorption from the injection depot, during which the MPA group reacts with available albumin at the site of injection and in systemic circulation. The terminal half-life of the conjugated species, measured via immunoassay detection of GHRH-reactive material in plasma, falls in the range of 6-8 days across multiple species. This contrasts sharply with the approximately 30-minute half-life of GHRH(1-29) and of CJC-1295 without DAC, which lack the albumin-binding moiety and remain exposed to rapid cleavage by circulating and tissue-bound peptidases, primarily dipeptidyl peptidase IV (DPP-IV) at the N-terminus. Maximum plasma concentrations (Cmax) following subcutaneous dosing appear at 24-72 hours post-administration, reflecting both the absorption phase and the time required for complete conjugation.
Resistance to Enzymatic Peptidase Degradation
Beyond the half-life extension attributable to albumin conjugation per se, the covalent attachment to a 67 kDa protein introduces steric protection against circulating peptidases. DPP-IV, which cleaves N-terminal His-Ala dipeptides from GHRH analogues and is the primary mechanism of rapid inactivation for native GHRH, faces substantially reduced access to the N-terminus of CJC-1295 when the peptide is tethered to the surface of albumin. Albumin’s three-domain architecture, while not encapsulating the peptide, does impose steric constraints around the conjugation point that partially shield the peptide backbone from productive peptidase binding. Additionally, the albumin-conjugated peptide is largely excluded from tissues where membrane-bound peptidases operate at high local concentrations, further reducing the effective rate of enzymatic inactivation relative to the unbound form. The net effect is a compound whose degradation kinetics are governed predominantly by the intrinsic half-life of albumin rather than by the peptide’s own susceptibility to enzymatic cleavage.
Section 4: Adjacent Research Areas
The pharmacokinetic strategy underlying CJC-1295 with DAC has parallels in other albumin-hitchhiking drug design approaches, including fatty acid conjugation strategies used in certain long-acting insulin and GLP-1 analogues. What distinguishes the DAC approach is the covalent, irreversible nature of the thioether bond, as opposed to the reversible non-covalent fatty acid-albumin interaction that governs compounds such as semaglutide. A covalent conjugate guarantees that once formed, the peptide-albumin complex does not dissociate and does not need to compete with endogenous fatty acids or other albumin ligands for binding site occupancy. This has implications for the predictability and consistency of pharmacokinetic behavior across animals with differing albumin occupancy states.
Preclinical bioavailability studies following subcutaneous administration in rats have reported absolute bioavailability values that account for both the absorption efficiency at the depot site and the efficiency of conjugation in the systemic compartment. The degree of conjugation is not perfectly complete under all experimental conditions, and the proportion of administered compound that successfully forms the stable thioether versus undergoing hydrolysis or reaction with low-molecular-weight thiols before reaching albumin represents a variable that affects exposure estimates. These nuances are pharmacologically meaningful and are relevant to any preclinical dose-response modeling using this compound as a research tool. All such data, and any experimental application of CJC-1295 with DAC, remain strictly within the domain of preclinical research use.
Observed Patterns (Non-Clinical Context)
Observed patterns worth noting, but not validated.
Outside of controlled studies, anecdotal reports and informal observations have noted persistent and prolonged alterations in appetite, sleep architecture, and recovery perception among individuals who have self-administered CJC-1295 with DAC in non-clinical settings. Some informal accounts have described what observers characterize as sustained elevations in subjective energy and body composition changes extending across multi-week intervals, consistent in timing with what preclinical pharmacokinetic data would predict from a compound exhibiting a 6-8 day effective half-life. Additional informal observations have noted a pattern of infrequent administration intervals compared to shorter-acting GHRH analogues, with some accounts referencing once-weekly or less frequent dosing schedules.
These observations carry no validated scientific standing. They are not derived from controlled environments, and the conditions under which they were noted lack standardized dosing protocols, verified compound identity, or reproducible measurement criteria. They should not be interpreted as validated outcomes, clinical findings, or evidence of efficacy or safety in any population. This section is presented solely to acknowledge the informal footprint surrounding this compound within non-clinical communities and does not constitute an endorsement, recommendation, or scientific claim of any kind.
Section 5: Limitations and Research Boundaries
The preclinical pharmacokinetic profile of CJC-1295 with DAC, defined by spontaneous covalent thioether formation at albumin Cys34 via the maleimidopropionic acid reactive group, represents a well-characterized example of endogenous protein hitchhiking as a half-life extension strategy. The shift from a 30-minute plasma half-life for the unconjugated peptide to a 6-8 day half-life for the albumin-conjugated species is mechanistically explained by the combination of albumin’s intrinsic longevity through FcRn-mediated recycling, the above-renal-threshold molecular weight of the conjugate, and the steric shielding from circulating peptidases conferred by attachment to a large plasma protein. The selectivity of the MPA-maleimide for the free thiol of Cys34, while not absolute, is sufficient under physiological conditions to produce consistent and reproducible pharmacokinetic behavior across rodent and non-human primate models.
For preclinical researchers employing CJC-1295 with DAC as a tool compound in GHRH receptor biology, growth hormone secretion dynamics, or sustained GHRH agonism paradigms, the pharmacokinetic parameters described here are essential design considerations. Dosing interval, plasma sampling strategy, immunoassay selection capable of distinguishing conjugated from free peptide, and species-specific albumin reactivity all factor into experimental design. The chemistry of the thioether conjugate, specifically its resistance to retro-Michael elimination following ring-opened hydrolysis, means that conjugate stability in stored plasma samples is generally reliable, though standard cold-chain precautions and protease inhibitor cocktails remain appropriate for bioanalytical work.
This compound is supplied and studied exclusively for research use only (RUO) purposes. No human or clinical application is implied, endorsed, or supported by the data summarized here, and all experimental use should conform to applicable institutional and regulatory oversight requirements governing peptide-based research agents. For those conducting or following peptide research, sourcing consistency and verifiable testing are often considered critical variables.
This article is for research and informational purposes only. The compounds discussed are Research Use Only (RUO) and have not received regulatory approval for human use. Nothing in this article constitutes medical advice or endorsement of any substance.